产品名称
12-NBD Stearate, Avanti Research™ - A Croda Brand 810110C
InChI
1S/C25H40N4O5/c1-3-4-5-12-15-20(16-13-10-8-6-7-9-11-14-17-23(30)31)28(2)21-18-19-22(29(32)33)25-24(21)26-34-27-25/h18-20H,3-17H2,1-2H3,(H,30,31)
InChI key
SAAVELCIPHKGJE-UHFFFAOYSA-N
assay
>99% (TLC)
form
liquid
packaging
pkg of 1 × 1 mL (810110C-1mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 810110C
concentration
1 mg/mL (810110C-1mg)
shipped in
dry ice
storage temp.
−20°C
正在寻找类似产品? 访问 产品对比指南
General description
12-NBD Stearate is a fluorescent long-chain fatty acid (LCFA) derivative. It is amphipathic and a non-esterifiable fatty acid probe for incorporation into lipid droplets.
Application
12-NBD Stearate may be used:
- as a ligand for fatty-acid binding protein 5 (FABP5) in competitive binding based high throughput fluorescence displacement assay
- as a ligand for FABPs in spectrofluorometric measurements
- as an inhibitor for FABP3, FABP5 and FABP7
Biochem/physiol Actions
12-NBD Stearate is unmetabolizable in HepG2 cells and colocalizes with α-caveolin-1 and its uptake is inhibited by filipin III. The sterol carrier protein-2 (SCP-2) 15-kDa isoform favors NBD Stearate transport compared to its 13.2-kDa isoform. The fatty-acid binding protein (FABP) expression in differentiating embryonic stem cells (ES) regulates the uptake of NBD Stearate. NBD Stearate is used majorly in fluorescence displacement binding assays of fatty-acid binding proteins.
Packaging
5 mL Amber Glass Screw Cap Vial (810110C-1mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
signalword
Danger
Hazard Classifications
Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3
target_organs
Central nervous system
存储类别
6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
wgk
WGK 3
flash_point_f
does not flash
flash_point_c
does not flash
法规信息
新产品
此项目有
Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors
Kaczocha M, et al.
The Journal of Biological Chemistry, 287(5), 3415-3424 (2012)
Targeting fatty acid binding protein (FABP) anandamide transporters-a novel strategy for development of anti-inflammatory and anti-nociceptive drugs
Berger WT, et al.
Testing, 7(12) (2012)
Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia
Kaczocha M, et al.
Testing, 9(4) (2014)
Targeting fatty acid binding protein (FABP) anandamide transporters-a novel strategy for development of anti-inflammatory and anti-nociceptive drugs
Berger WT, et al.
PLoS ONE, 7(12) (2012)
M T Milliano et al.
Hepatology (Baltimore, Md.), 33(2), 413-418 (2001-02-15)
The role of cytosolic fatty acid binding protein (FABP) in cellular fatty acid metabolism remains poorly defined. The intracellular movement of fatty acids is thought to be facilitated through codiffusion with FABP. Peroxisomal proliferators like clofibrate induce FABP and may
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持